Rigetti is starting to look less like a science project and more like a real supplier, with early signs that customers are actually buying its quantum machines and using its cloud access. The catch: the company is still burning cash and has to hit tough technical goals, so even small stumbles could hit confidence fast.Read more

IonQ is pulling ahead in the race to turn quantum computing from lab work into real customer work, with growing demand and a broader push into related technologies like networking and manufacturing. But the market already treats it like a sure long-term winner, so even a small stumble in execution or the tech roadmap could hit the stock hard.Read more

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Rating: Buy / Quality recovery compounder Style: Mid-cap consumer compounder with cyclical film-slate exposure Core debate: Is Kinepolis just a movie-theatre operator in a structurally challenged industry, or is it a premium cinema platform with better economics, stronger pricing power, and more durable cash generation than the market gives it credit for? Executive view Kinepolis is not a “cinema recovery trade” in the simple sense.Read more

Rating: Speculative Buy / High-risk value Style: Leveraged offshore E&P recovery Core debate: Is Kosmos just another debt-heavy small-cap oil and gas producer, or is it an underappreciated offshore cash-flow story with improving production, falling costs, and meaningful equity upside if management keeps deleveraging? Executive view Kosmos is not a “quality compounder” in the way Prysmian or Quanta are.Read more

Rating: Speculative / Venture-style public equity Style: Pre-revenue aerospace development story Core debate: Is Horizon Aircraft a differentiated eVTOL platform with a more practical mission profile than many peers, or is it still too early, too capital-intensive, and too uncertain to justify meaningful equity upside today? Executive view Horizon Aircraft is not an established aerospace manufacturer.Read more

Rating: High-Quality Compounder / Buy on pullbacks Style: Infrastructure-led secular grower Core debate: Is Quanta simply an expensive contractor riding an unusually strong capex cycle, or is it the best-positioned execution platform for a multi-year grid, electrification, and AI-power buildout that deserves a premium multiple? Executive view Quanta is one of the clearest “picks-and-shovels” beneficiaries of the U.S. power infrastructure supercycle.Read more

Rating: Buy / Quality Cyclical Growth Style: Aerospace OEM with backlog-driven visibility and multi-segment optionality Core debate: Is Embraer simply a smaller aircraft manufacturer benefiting from an aerospace upcycle, or is it a niche aerospace platform with durable competitive positions, improving margins, and an unusually attractive backlog-to-revenue profile? Executive view Embraer looks increasingly like one of the more attractive ways to invest in aerospace without taking full exposure to the execution problems and balance-sheet complexity of the largest airframers.Read more

Rating: Speculative Buy / Deep-Value Metals PlayStyle: Cyclical mining and smelting with zinc leverage and balance-sheet repair Core debate: Is Nexa just a cheap Latin American zinc name trapped in a volatile commodity cycle, or is it an underappreciated integrated base-metals platform with real cash-flow torque, diversified by-products, and upside if zinc fundamentals tighten further? Executive view Nexa is one of the cheaper ways to gain exposure to zinc and related base metals, but the investment case is stronger than a simple commodity beta trade.Read more